Background:
Bruton’s tyrosine kinase (BTK) plays an important role in cell development and proliferation. BTK inhibitors are encouraging novel agents against B-cell malignancies and autoimmune diseases. Although BTK inhibitors have been approved by the FDA, but to lower off-target effects and to reduce emerging resistances, it is necessary to develop novel BTK inhibitors with better outcomes and minimum side effects.
Objective:
The present study includes pharmacophore hypothesis, 3D QSAR, virtual screening, docking, ADME analysis and screening of potential imidazo[1,5-a]pyrazine derivatives as BTK inhibitors. Methods: Generation of pharmacophore hypothesis, virtual screening, 3D QSAR, molecular docking and ADME analysis.
Methods:
Generation of pharmacophore hypothesis, virtual screening, 3D QSAR, molecular docking and ADME analysis.
Results:
Pharmacophore study generated 20 pharmacophore hypotheses as BTK inhibitor. The five-point hypothesis DPRRR_1 were selected, consist one hydrogen bond donor, one positive ionic, and three ring aromatic features. 3D QSAR study of the compounds provided the best model with high Q2 (0.8683), R2 (0.983) and R2CV (0.5338) values. The developed pharmacophore model was further taken for screening of ZINC database ligands for evaluation of docking interaction and physiochemical properties. Potent compounds of the series 15, 27, 8n and 38 showed good docking scores -8.567, -7.465, -6.922, -6.137, respectively.
Conclusion:
All the pharmacokinetic parameters analysed, including human oral absorption of active compounds of the series were found to be within the permissible range. The present geometry and features included in pharmacophore hypothesis can be used for the development of novel BTK inhibitors as anticancer agents.
